FDA Issued Warning Letters Regarding Fake COVID-19 Products
The U.S. Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) issued warning letters to 7 companies for selling fraudulent COVID-19 products.
The warning letters are the first to be issued by the FDA for unapproved products intended to prevent or treat “Novel Coronavirus Disease 2019” (COVID-19).
These products are unapproved drugs that pose significant risks to patient health and violate federal law.
In a press statement published on March 9, 2020, both the FDA and FTC said they are taking these actions to protect Americans during the global COVID-19 disease outbreak.
Furthermore, the FDA is particularly concerned that products that claim to cure, treat or prevent serious diseases like COVID-19 may cause consumers to delay or stop appropriate medical treatment, leading to serious and life-threatening harm.
The products cited in these warning letters are teas, essential oils, tinctures, and colloidal silver.
“The FDA considers the sale and promotion of fraudulent COVID-19 products to be a threat to public health. We have an aggressive surveillance program that routinely monitors online sources for health fraud products, especially during a significant public health issue such as this one,” said FDA Commissioner Stephen M. Hahn, M.D.
“We understand consumers are concerned about the spread of COVID-19 and urge them to talk to their health care providers, as well as follow advice from other federal agencies about how to prevent the spread of this illness.”
“We will continue to aggressively pursue those that place the public health at risk and hold bad actors accountable.”
The FDA and FTC jointly issued warning letters to the following companies:
- Vital Silver
- Quinessence Aromatherapy Ltd
- Xephyr, LLC doing business as N-Ergetics
- GuruNanda, LLC
- Vivify Holistic Clinic
- Herbal Amy LLC
- The Jim Bakker Show
Companies that sell products that fraudulently claim to prevent, treat or cure COVID-19 may be subject to legal action, including but not limited to seizure or injunction.
In addition to following up with companies that fail to make adequate corrections, the FDA and FTC will continue to monitor social media, online marketplaces, and incoming complaints to help ensure that the companies do not continue to sell fraudulent products under a different company name or on another website.
An FDA cross-agency task force has been established and dedicated to closely monitor for fraudulent products related to COVID-19.
The FDA reminds consumers to be cautious of websites and stores selling products that claim to prevent, mitigate, treat, diagnose or cure COVID-19. Fraudulent COVID-19 products may come in many varieties, including dietary supplements and other foods, as well as products purporting to be drugs, medical devices or vaccines.
The FDA encourages healthcare professionals and consumers to report adverse events or quality problems experienced with the use of COVID-19 products to the FDA’s MedWatch Adverse Event Reporting program.
The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.
COVID-19 outbreak news is published by Coronavirus Today.
FDA product news is published by Precision Vaccinations.